“…Notably recurrent mutations have been observed in acute myeloid leukemia (AML) cases de novo AML and AML with myelodysplasia-related changes (10-20%), down syndrome-associated acute megakaryoblastic leukemia (50% DS-AMKL), myelodysplastic syndromes (5-15%), and myeloproliferative neoplasms (MPNs; up to 10%), as classified according to the 2008 WHO classification for hematopoietic and lymphoid tissue (Ding et al, 2012;Cancer Genome Atlas Research Network, 2013;Kon et al, 2013;Nikolaev et al, 2013;Yoshida et al, 2013;Thol et al, 2014;Thota et al, 2014;Lindsley et al, 2015). In addition, somatic mutations have been found in a wide range of solid cancers like bladder cancer (20%) and Ewing's sarcoma (20%; Balbás-Martínez et al, 2013;Guo et al, 2013;Solomon et al, 2013;Crompton et al, 2014;Tirode et al, 2014). Besides the aforementioned somatic mutations, germline mutations of cohesin have been described in patients with developmental syndromes, particularly Cornelia de Lange syndrome (CdLS; Mannini et al, 2013).…”